Gsa Capital Partners LLP Arcus Biosciences, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 187,415 shares of RCUS stock, worth $2.63 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
187,415
Previous 159,108
17.79%
Holding current value
$2.63 Million
Previous $2.42 Million
18.28%
% of portfolio
0.22%
Previous 0.17%
Shares
17 transactions
Others Institutions Holding RCUS
# of Institutions
200Shares Held
51.5MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$137 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$76.7 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$48.8 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$42.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$34.2 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.01B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...